Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Glythera Receives Funding Boost

Published: Tuesday, July 09, 2013
Last Updated: Thursday, July 11, 2013
Bookmark and Share
Investment will progress the development of a new generation of biological therapeutics through advanced glycosylation technologies.

Glythera Ltd announces that it has successfully achieved a number of technical and commercial milestones which has resulted in the release of a second tranche of funding totalling £700k from IP Group and its managed fund, the Finance for Business North East Technology Fund.

Glythera, a UK based spin out specialising in a new generation of biological therapeutics through advanced glycosylation technologies, received an initial investment of £600,000 in April 2012.The funds have been used by the company to continue the development of a new generation of biological therapeutics including its core technologies - Permalink™ and Permacarb™. These technologies will be used to create drugs with unprecedented biological stability, bioavailability and therapeutic efficacy.

Glythera reached its technical and commercial targets ahead of schedule including the validation of Glythera’s Permalink™ technology and establishment of partnerships with four pharmaceutical companies. This demonstrates how the company is effectively managing the financial investment it has received. The third tranche of investment will be made available once further technological progress has been made and commercial traction successfully achieved. 

Glythera is based in the Newcastle-upon-Tyne INEX incubator facility, ideally placed within the North East of England which is fast becoming one of the top ten places in the world to do science based business. With the financial support from IP Group, Glythera is continuing to establish itself within the region and has demonstrated its commitment to growth with the creation of seven new jobs. 

The additional investment coincides with Glythera consolidating its board of directors with the addition of Cassie Doherty from IP Group. With a wealth of expertise and experience in commercial development Cassie’s appointment represents a significant benefit to the company in achieving specific business development related outcomes. Cassie completes a team of three that comprises the board of directors at Glythera including CEO of Cyprotex and Chairman of Equinox Pharma Dr Anthony  Baxter and William Bains representing Bath University. 

Commenting on the investment Dr Baxter said, “Glythera is a shining example of how a spin out company can be successfully brought to commercialisation. By meeting the criteria to receive the second installment of funding it has shown that it is capable of developing innovative technology in a challenging market. I am extremely pleased to be involved at this exciting time for the company and I look forward to continuing to working with the team as it leads the way in the development of ground breaking biological therapeutics for the benefit of the pharmaceutical industry.” 

Chief Operating Officer Dr. David Simpson said, “We are delighted with the progress that has been made throughout the research and development process so far thanks to the expertise of the Glythera team in the discovery, development and manufacturing of complex biologics. This funding will enable us to continue with the commercialisation of our products and maximise the opportunities available to us in the market.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Zika Vaccines Prevent Disorders in Newborn Mice
Disorder immunity transmitted from female mice to pups following vaccination with two Zika vaccines.
Antibody Drug Conjugates May Help Personalize Radiotherapy
Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos